Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A compound of formula (I)



(I)

in which:

R^1 is an aryl group, optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from $C_{(1-6)}$alkyl, $C_{(1-6)}$alkoxy, $C_{(1-6)}$alkylthio, arylC(1-6)alkoxy, hydroxy, halogen, CN, COR^7, carboxy, $COOR^7$, NR^7COR^8, $CONR^9R^{10}$, $SO_2NR^9R^{10}$, $NR^7SO_2R^8$, NR^9R^{10}, mono to perfluoro-$C_{(1-4)}$alkyl, mono to perfluoro-$C_{(1-4)}$alkoxyaryl, and aryl$C_{(1-4)}$alkyl;

R^2 is halogen, $C_{(1-3)}$alkyl, $C_{(1-3)}$alkoxy, hydroxy$C_{(1-3)}$alkyl, $C_{(1-3)}$alkylthio, $C_{(1-3)}$alkylsulphinyl, amino$C_{(1-3)}$alkyl, mono- or di-$C_{(1-3)}$alkylamino$C_{(1-3)}$alkyl, $C_{(1-3)}$alkylcarbonylamino$C_{(1-3)}$alkyl, $C_{(1-3)}$alkoxy$C_{(1-3)}$alkylcarbonylamino$C_{(1-3)}$alkyl, $C_{(1-3)}$alkylsulphonylamino$C_{(1-3)}$alkyl, $C_{(1-3)}$alkylcarboxy, $C_{(1-3)}$alkylcarboxy$C_{(1-3)}$alkyl, and

R^3 is hydrogen, halogen, $C_{(1-3)}$alkyl, or hydroxy$C_{(1-3)}$alkyl; or

R^2 and R^3 together with the pyridone or pyrimidone ring carbon atoms to which they are attached form a fused 5-or 6-membered carbocyclic ring; or

R^2 and R^3 together with the pyridone or pyrimidone ring carbon atoms to which they are attached form a fused benzo or heteroaryl ring optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from halogen, $C_{(1-4)}$alkyl, cyano, $C_{(1-3)}$alkoxy$C_{(1-3)}$alkyl, $C_{(1-4)}$alkoxy or $C_{(1-4)}$alkylthio, or mono to perfluoro-$C_{(1-4)}$alkyl;

R^4 is $(CH_2)_n$ substituted by a substituent selected from benzimidazole or a 5- or 6-membered heteroaryl, each of which may optionally be substituted by one or more R^{11};

R^5 is an aryl or a heteroaryl ring optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from $C_{(1-6)}$alkyl, $C_{(1-6)}$alkoxy, $C_{(1-6)}$alkylthio, aryl$C_{(1-6)}$alkoxy, hydroxy, halogen, CN, COR^7, carboxy, $COOR^7$, NR^7COR^8, $CONR^9R^{10}$, $SO_2NR^9R^{10}$, $NR^7SO_2R^8$, NR^9R^{10}, mono to perfluoro-$C_{(1-4)}$alkyl and mono to perfluoro-$C_{(1-4)}$alkoxy;

R^6 is an aryl or a heteroaryl ring which is further optionally substituted by 1, 2, 3 or 4 substituents which may be the same or different selected from $C_{(1-6)}$alkyl, $C_{(1-6)}$alkoxy, $C_{(1-6)}$alkylthio, $C_{(1-6)}$alkylsulfonyl, aryl$C_{(1-6)}$alkoxy, hydroxy, halogen, CN, COR^7, carboxy, $COOR^7$, $CONR^9R^{10}$, NR^7COR^8, $SO_2NR^9R^{10}$, $NR^7SO_2R^8$, NR^9R^{10}, mono to perfluoro-$C_{(1-4)}$alkyl and mono to perfluoro-$C_{(1-4)}$alkoxy, or $C_{(5-10)}$alkyl;

R^7 and R^8 are independently hydrogen or C $_{(1-12)}$alkyl, for instance $C_{(1-4)}$alkyl (e.g. methyl or ethyl);

R^9 and R^{10} which may be the same or different is each selected from hydrogen, or $C_{(1-12)}$alkyl, or R^9 and R^{10} together with the nitrogen to which they are attached form a 5- to 7 membered ring optionally containing one or more further heteroatoms selected from oxygen, nitrogen and sulphur, and optionally substituted by one or two substituents selected from hydroxy, oxo, $C_{(1-4)}$alkyl, $C_{(1-4)}$alkylcarboxy, aryl, e.g. phenyl, or aralkyl, e.g benzyl, for instance morpholine or piperazine;

R^{11} is selected from the group consisting of halogen, CF_3, $C_{(1-6)}$alkyl, $C_{(1-6)}$alkoxy $C_{(1-6)}$alkyl or benzyl optionally substituted by CF_3, $C_{(1-6)}$alkyl, $C_{(1-6)}$alkoxy or halogen;

X is CH or nitrogen;

Y is $C_{(2-4)}$alkylene group (optionally substituted by 1, 2 or 3 substituents selected from methyl and ethyl), CH=CH, or $(CH_2)_mS$;

n is 1, 2, 3 or 4; and

m is 1 or 2,

or a pharmaceutically acceptable salt thereof.

2. (Original) A compound according to claim 1 wherein R^1 is phenyl optionally substituted by 1, 2, 3 or 4 halogen substituents.

3. (Original) A compound according to claim 2 wherein R^1 is phenyl substituted by 1 to 3 fluoro.

4. (Currently Amended) A compound according to ~~any of claims 1 to 3~~ claim 1 wherein X is CH and R^2 and R^3 together with the pyridone ring carbon atoms to which they are attached form an unsubstituted fused benzo or pyrido ring.

5. (Currently Amended) A compound according to ~~any of claims 1 to 3~~ claim 1 wherein X is N and R^2 and R^3 together with the pyrimidone ring carbon atoms to which they are attached form an unsubstituted fused benzo or cyclopentenyl ring.

6. (Currently Amended) A compound according to ~~any of claims 1 to 5~~ claim 1 wherein R^4 is $(CH_2)_n$ substituted by benzimidazolyl, imidazolyl, thiazolyl, pyrazolyl, tetrazolyl and pyridyl each of which may be optionally further substituted by one or more R^{11}.

7. (Original) A compound according to claim 6 wherein the benzimidazolyl, imidazolyl, thiazolyl, pyrazolyl, tetrazolyl or pyridyl ring is unsubstituted or substituted by one or two substituents selected from halogen, $C_{(1-6)}$ alkyl and $C_{(1-6)}$ alkoxy$C_{(1-6)}$ alkyl.

8. (Original) A compound according to clam 7 wherein the benzimidazolyl , imidazolyl, thiazolyl, pyrazolyl, tetrazolyl or pyridyl ring is substituted by one or two substituents selected from chloro, fluoro, bromo, $C_{(1-4)}$ alkyl and $C_{(1-3)}$ alkoxy $C_{(1-3)}$ alkyl.

9. (Currently Amended) A compound according to ~~any of claims 1 to 8~~ claim 1 wherein R^5 is phenyl or pyridyl.

10. (Currently Amended) A compound according to ~~any of claims 1 to 9~~ claim 1 wherein R^6 is phenyl substituted by mono to perfluoro- $C_{(1-4)}$ alkyl, halogen or $C_{(1-6)}$) alkyl.

11. (Currently Amended) A compound according to ~~any of claims 1 to 10~~ claim 1 wherein R^5 is phenyl and R^6 is phenyl optionally substituted by trifluoromethyl.

12. (Currently Amended) A compound according to ~~any of claims 1 to 11~~ claim 1 wherein Y is CH_2S or $(CH_2)_2$.

13. (Cancelled)

14. (Currently Amended) A pharmaceutical composition comprising a compound of formula (I) as defined in ~~any of claims 1 to 13~~ claim 1 and a pharmaceutically acceptable carrier, optionally with one or more other therapeutic compounds.

15. (Cancelled)

16. (Cancelled)

17. (Currently Amended) A method of treating a disease associated with activity of the enzyme Lp-PLA_2 which method involves treating a patient in need thereof with a therapeutically effective amount of a compound of formula (I) as defined in ~~any of claims 1 to 13~~ claim 1.

18. (Original) A process for preparing a compound of formula (I) as defined in claim 1 which process comprises reacting an acid compound of formula (II):



(II)

in which X, Y, R^1, R^2 and R^3 are as hereinbefore defined,
with an amine compound of formula (III):

$$R^6\text{-}R^5\text{-}CH_2NHR^4$$

(III)

in which R^4, R^5 and R^6 are as hereinbefore defined; under amide forming conditions